In conclusion, the work by Xu et al published in the current issue of EMBO Molecular Medicine delineates a druggable metabolic addiction of NF2-deficient mesothelioma to pyrimidine and offers a novel translational opportunity to treat this otherwise intractable neoplasm. The gene discussed is NF2; the disease is mesothelioma.